Related Experiment Video
Updated: Mar 6, 2026

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
Published on: June 14, 2021
Maculopapular-Type Drug Eruption Caused by Cetuximab.
Noriko Ikegawa1, Natsuko Saito-Sasaki1, Yu Sawada1
1Dermatology, University of Occupational and Environmental Health, Kitakyushu, JPN.
Cetuximab can cause rare delayed skin reactions. This case highlights type IV hypersensitivity, emphasizing careful monitoring during cancer treatment.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Cetuximab (cetuximab), an IgG1 monoclonal antibody, targets the epidermal growth factor receptor.
- Immediate hypersensitivity reactions to cetuximab are common, mediated by IgE antibodies to the α-gal epitope.
- Type IV T-cell-mediated hypersensitivity reactions are rare.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
Drug Toxicity: Allergic Reactions
Allergic Drug Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Hypersensitivity Reactions: Immune-Complex Reactions
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Drug toxicity: Idiosyncratic Reactions